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UVEITIS STUDIES
Patients who were diagnosed as suffering from acute anterior uveitis were selected for these studies. The nature and purpose of the studies were explained to the patients, after which they gave their consent to participate in the investigation. Each Patients were assessed initially and at approximately weekly intervals for 3 or 4 weeks. In studies 1 and 2 the following signs and symptoms were scored on a 0 to 3 scale (where 0 is absent and 3 is severe): blurring, redness, watering, photophobia, pain, ciliary injection, corneal oedema, keratic precipitates, flare, cells, and exudate. The assessment of treatment was considered to be 'good' if the total score fell to between 0 and 2 within 3 to 4 weeks, 'satisfactory' if the score fell to between 3 and 7, and 'poor' if there was no reduction in score or patients were withdrawn because of a worsening of the disease. In study 3 only the signs of the disease were recorded as above, and in addition the clinician assessed the response as good, satisfactory, or poor after 3 weeks' treatment. In study 4 the response at each visit was assessed as 644
Clinical evaluation ofclobetasone butyrate eye drops in the treatment ofanterior uveitis patients. Fig. 1 shows the individual results and Table  2 summarises the patients' response to treatment. One patient received clobetasone butyrate in both eyes, and one in each group was withdrawn because of a worsening of the uveitis. The patient withdrawn from the betainethasone group also complained that the drops caused stinging on instillation. 
Clinical evaluation ofclobetasone butyrate eye drops in the treatnent ofanterior uveitis patients with betamethasone phosphate in 13 patients. The results given in Table 2 are the ophthalmologists' assessment after 3 to 4 weeks of treatment. Only one patient in each group had a poor response to the topical steroid treatment.
INTRAOCULAR PRESSURE STUDY
None of the 6 patients receiving clobetasone butyrate and neomycin eye drops experienced a significant rise in their intraocular pressure (i.e., greater than 6 mmHg) during the 6 weeks of the study (Table 3) .
However, rises of between 11 and 26 mmHg were experienced by the 4 patients receiving dexamethasone over a similar period of time. Two patients receiving hydrocortisone and neomycin over a4-week period had rises of 10 and 11 mmHg respectively.
Discussion
From these clinical results it can be seen that clobetasone butyrate is effective in the treatment of anterior uveitis. In the 4 studies 87% of the patients treated with clobetasone butyrate had a good or satisfactory response after 3 weeks' treatment, and this was comparable to the 81% and the 80% of patients showing such a response after treatment with betamethasone phosphate and prednisolone phosphate respectively.
Dunne and Travers' clearly showed the benefit of treating anterior uveitis with clobetasone butyrate or betamethasone eye drops compared with a placebo eye preparation. They did not, however, demonstrate a statistically significant difference in sign and symptom scores from patients receiving the steroid or placebo because of the limited number of patients studied. Although in many patients anterior uveitis is a self-limiting disease, steroids are of benefit in resolving the signs and symptoms quickly.
Previous studies have established that clobetasone butyrate has a minimal effect on intraocular pressure when compared with dexamethasone,' betamethasone,2 and prednisolone.3 The results of this investigation have confirmed the reduced propensity of clobetasone butyrate to raise intraocular pressure in known steroid responders when compared with dexamethasone and hydrocortisone. The significant intraocular pressure effect of hydrocortisone eye drops (with or without neomycin) has been confirmed by intraocular pressure and aqueous outflow measurements (Mapstone R, personal communication, 1980). In view of its reduced propensity to raise intraocular pressure, clobetasone butyrate would appear to be a useful new steroid preparation, having good anti-inflammatory activity and less effect on intraocular pressure than dexamethasone, betamethasone, prednisolone, and hydrocortisone. 
